Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

The Rationale and Efficacy of Primary and Secondary Prevention in Adenocarcinomas of the Upper Gastrointestinal Tract.

Bornschein J, Bird-Lieberman EL, Malfertheiner P.

Dig Dis. 2019 Apr 10:1-13. doi: 10.1159/000499706. [Epub ahead of print] Review.

2.

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, Sutton EK, Stevenson L, McManus D, Halliday S, McCavigan AM, Logan GE, Walker SM, Steele CJ, Perner J, Bornschein J, MacRae S, Miremadi A, McCarron E, McQuaid S, Arthur K, James JA, Eatock MM, O'Neill R, Noble F, Underwood TJ, Harkin DP, Salto-Tellez M, Fitzgerald RC, Kennedy RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group.

Gut. 2019 Mar 9. pii: gutjnl-2018-317624. doi: 10.1136/gutjnl-2018-317624. [Epub ahead of print]

3.

Author Correction: Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.

Garcia E, Hayden A, Birts C, Britton E, Rogerson C, Bleaney CW, Cowie A, Pickard K, Mellone M, Choh C, Derouet M, Duriez P, Noble F, White MJ, Primrose JN, Strefford JC, Rose-Zerilli M, Thomas GJ, Ang Y, Sharrocks AD, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Sci Rep. 2019 Jan 22;9(1):318. doi: 10.1038/s41598-018-37591-7.

4.

Combined Gastric and Colorectal Cancer Screening-A New Strategy.

Selgrad M, Bornschein J, Kandulski A, Weigt J, Roessner A, Wex T, Malfertheiner P.

Int J Mol Sci. 2018 Dec 3;19(12). pii: E3854. doi: 10.3390/ijms19123854.

5.

Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial.

Mohnike K, Steffen IG, Seidensticker M, Hass P, Damm R, Peters N, Seidensticker R, Schütte K, Arend J, Bornschein J, Streitparth T, Wybranski C, Wieners G, Stübs P, Malfertheiner P, Pech M, Ricke J.

Cardiovasc Intervent Radiol. 2019 Feb;42(2):239-249. doi: 10.1007/s00270-018-2127-5. Epub 2018 Nov 28.

PMID:
30488303
6.

Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts.

Sawas T, Killcoyne S, Iyer PG, Wang KK, Smyrk TC, Kisiel JB, Qin Y, Ahlquist DA, Rustgi AK, Costa RJ, Gerstung M, Fitzgerald RC, Katzka DA; OCCAMS Consortium.

Gastroenterology. 2018 Dec;155(6):1720-1728.e4. doi: 10.1053/j.gastro.2018.08.036. Epub 2018 Aug 27.

PMID:
30165050
7.

[Colorectal cancer prevention in Europe - where do we stand?]

Bornschein J, Teufel A.

Z Gastroenterol. 2018 Apr;56(4):401-403. doi: 10.1055/s-0044-102024. Epub 2018 Apr 11. German. No abstract available.

PMID:
29642254
8.

Corrigendum: A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy.

Noorani A, Bornschein J, Lynch AG, Secrier M, Achilleos A, Eldridge M, Bower L, Weaver JMJ, Crawte J, Ong CA, Shannon N, MacRae S, Grehan N, Nutzinger B, O'Donovan M, Hardwick R, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium.

Genome Res. 2017 Oct;27(10):1782. doi: 10.1101/gr.229153.117. No abstract available.

9.

Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.

Noble F, Lloyd MA, Turkington R, Griffiths E, O'Donovan M, O'Neill JR, Mercer S, Parsons SL, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Br J Surg. 2017 Dec;104(13):1816-1828. doi: 10.1002/bjs.10627. Epub 2017 Sep 25.

10.

Regulation of apoptosis is impaired in atrophic gastritis associated with gastric cancer.

Rosania R, Varbanova M, Wex T, Langner C, Bornschein J, Giorgio F, Ierardi E, Malfertheiner P.

BMC Gastroenterol. 2017 Jun 29;17(1):84. doi: 10.1186/s12876-017-0640-7.

11.

A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy.

Noorani A, Bornschein J, Lynch AG, Secrier M, Achilleos A, Eldridge M, Bower L, Weaver JMJ, Crawte J, Ong CA, Shannon N, MacRae S, Grehan N, Nutzinger B, O'Donovan M, Hardwick R, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium.

Genome Res. 2017 Jun;27(6):902-912. doi: 10.1101/gr.214296.116. Epub 2017 May 2. Erratum in: Genome Res. 2017 Oct;27(10 ):1782.

12.

[Regorafenib - a revolution in the systemic treatment options of HCC?]

Bornschein J, Schlosser S.

Z Gastroenterol. 2017 Jul;55(7):685-686. doi: 10.1055/s-0043-106861. Epub 2017 Apr 24. German. No abstract available.

PMID:
28437801
13.

Corrigendum: Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.

Secrier M, Li X, de Silva N, Eldridge MD, Contino G, Bornschein J, MacRae S, Grehan N, O'Donovan M, Miremadi A, Yang TP, Bower L, Chettouh H, Crawte J, Galeano-Dalmau N, Grabowska A, Saunders J, Underwood T, Waddell N, Barbour AP, Nutzinger B, Achilleos A, Edwards PA, Lynch AG, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium.

Nat Genet. 2017 Jan 31;49(2):317. doi: 10.1038/ng0217-317a. No abstract available.

PMID:
28138154
14.

S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease.

Authors; Responsible in representation of the DGVS:.

Z Gastroenterol. 2017 Feb;55(2):167-206. doi: 10.1055/s-0042-119653. Epub 2016 Dec 5. No abstract available.

15.

Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.

Garcia E, Hayden A, Birts C, Britton E, Cowie A, Pickard K, Mellone M, Choh C, Derouet M, Duriez P, Noble F, White MJ, Primrose JN, Strefford JC, Rose-Zerilli M, Thomas GJ, Ang Y, Sharrocks AD, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Sci Rep. 2016 Sep 7;6:32417. doi: 10.1038/srep32417. Erratum in: Sci Rep. 2019 Jan 22;9(1):318.

16.

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.

Secrier M, Li X, de Silva N, Eldridge MD, Contino G, Bornschein J, MacRae S, Grehan N, O'Donovan M, Miremadi A, Yang TP, Bower L, Chettouh H, Crawte J, Galeano-Dalmau N, Grabowska A, Saunders J, Underwood T, Waddell N, Barbour AP, Nutzinger B, Achilleos A, Edwards PA, Lynch AG, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium.

Nat Genet. 2016 Oct;48(10):1131-41. doi: 10.1038/ng.3659. Epub 2016 Sep 5. Erratum in: Nat Genet. 2017 Jan 31;49(2):317.

17.

[S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease].

Fischbach W, Malfertheiner P, Lynen Jansen P, Bolten W, Bornschein J, Buderus S, Glocker E, Hoffmann JC, Koletzko S, Labenz J, Mayerle J, Miehlke S, Mössner J, Peitz U, Prinz C, Selgrad M, Suerbaum S, Venerito M, Vieth M; Verantwortlich für die DGVS.

Z Gastroenterol. 2016 Apr;54(4):327-63. German. No abstract available. Erratum in: Z Gastroenterol. 2016 Apr;54(4):1.

PMID:
27512738
18.

Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma.

Gregson EM, Bornschein J, Fitzgerald RC.

Br J Cancer. 2016 Aug 9;115(4):403-10. doi: 10.1038/bjc.2016.219. Epub 2016 Jul 21. Review.

19.

[New classification of gastric cancer - is the Laurén classification obsolete?].

Bornschein J.

Z Gastroenterol. 2016 Jul;54(7):661-2. doi: 10.1055/s-0042-102465. Epub 2016 Jul 18. German. No abstract available.

PMID:
27429104
20.

[S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease].

Fischbach W, Malfertheiner P, Lynen Jansen P, Bolten W, Bornschein J, Buderus S, Glocker E, Hoffmann CJ, Koletzko S, Labenz J, Mayerle J, Miehlke S, Mössner J, Peitz U, Prinz C, Selgrad M, Suerbaum S, Venerito M, Vieth M; Verantwortlich für die DGVS.

Z Gastroenterol. 2016 Apr;54(4):1. doi: 10.1055/s-0035-1567086. Epub 2016 May 11. German.

Supplemental Content

Loading ...
Support Center